GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (NAS:MDGL) » Definitions » E10

Madrigal Pharmaceuticals (Madrigal Pharmaceuticals) E10 : $-19.99 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Madrigal Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Madrigal Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $-7.380. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-19.99 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 7.80% per year. During the past 5 years, the average E10 Growth Rate was -0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Madrigal Pharmaceuticals was 30.00% per year. The lowest was -12.60% per year. And the median was 7.80% per year.

As of today (2024-05-23), Madrigal Pharmaceuticals's current stock price is $235.06. Madrigal Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $-19.99. Madrigal Pharmaceuticals's Shiller PE Ratio of today is .


Madrigal Pharmaceuticals E10 Historical Data

The historical data trend for Madrigal Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals E10 Chart

Madrigal Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.91 -25.72 -24.70 -23.24 -20.18

Madrigal Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.69 -21.90 -21.11 -20.18 -19.99

Competitive Comparison of Madrigal Pharmaceuticals's E10

For the Biotechnology subindustry, Madrigal Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Madrigal Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's Shiller PE Ratio falls into.



Madrigal Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Madrigal Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-7.38/131.7762*131.7762
=-7.380

Current CPI (Mar. 2024) = 131.7762.

Madrigal Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -8.400 100.560 -11.008
201409 -6.650 100.428 -8.726
201412 -6.300 99.070 -8.380
201503 -6.650 99.621 -8.796
201506 -5.250 100.684 -6.871
201509 -10.460 100.392 -13.730
201512 -10.880 99.792 -14.367
201603 -9.720 100.470 -12.749
201606 -16.330 101.688 -21.162
201609 -1.590 101.861 -2.057
201612 -0.670 101.863 -0.867
201703 -0.500 102.862 -0.641
201706 -0.690 103.349 -0.880
201709 -0.680 104.136 -0.860
201712 -0.670 104.011 -0.849
201803 -0.450 105.290 -0.563
201806 -0.450 106.317 -0.558
201809 -0.560 106.507 -0.693
201812 -0.750 105.998 -0.932
201903 -0.980 107.251 -1.204
201906 -1.280 108.070 -1.561
201909 -1.390 108.329 -1.691
201912 -1.800 108.420 -2.188
202003 -2.340 108.902 -2.832
202006 -3.180 108.767 -3.853
202009 -3.750 109.815 -4.500
202012 -3.820 109.897 -4.581
202103 -3.320 111.754 -3.915
202106 -3.720 114.631 -4.276
202109 -3.790 115.734 -4.315
202112 -3.780 117.630 -4.235
202203 -3.360 121.301 -3.650
202206 -4.140 125.017 -4.364
202209 -4.750 125.227 -4.998
202212 -4.980 125.222 -5.241
202303 -4.230 127.348 -4.377
202306 -4.690 128.729 -4.801
202309 -5.340 129.860 -5.419
202312 -5.720 129.419 -5.824
202403 -7.380 131.776 -7.380

Add all the adjusted EPS together and divide 10 will get our e10.


Madrigal Pharmaceuticals  (NAS:MDGL) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Madrigal Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Madrigal Pharmaceuticals (Madrigal Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Executives
Robert E. Waltermire officer: Senior VP, Chief Pharma Dev. FOUR TOWER BRIDGE, 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN PA 19428
Baker Bros. Advisors Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian Joseph Lynch officer: SVP and General Counsel 480 MORRIS ROAD, BLUE BELL PA 19422
William John Sibold director, officer: President and CEO C/O MADRIGAL PHARMACEUTICALS, INC., FOUR, TOWER BRIDGE, 200 BARR HARBOR DR STE 200, WEST CONSHOHOCKEN PA 19428
Felix Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Raymond Cheong director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Remy Sukhija officer: SVP and Chief Comm'l Officer 48 PHEASANT HILL ROAD, PRINCETON NJ 08540
Alex G. Howarth officer: Chief Financial Officer C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Bay City Capital Llc 10 percent owner 750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Fred B Craves director, 10 percent owner 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111